MLICM
TEVA icon

Metropolitan Life Insurance Company (MetLife)’s Teva Pharmaceuticals TEVA Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-43,972
Closed -$620K – 1904
2024
Q1 		$620K Hold
43,972
– – 0.03% 438
2023
Q4 		$459K Hold
43,972
– – 0.02% 477
2023
Q3 		$449K Sell
43,972
-2,900
-6% -$27K 0.02% 462
2023
Q2 		$353K Hold
46,872
– – 0.02% 515
2023
Q1 		$415K Sell
46,872
-6,200
-12% -$61.3K 0.02% 493
2022
Q4 		$484K Sell
53,072
-4,400
-8% -$38.4K 0.02% 495
2022
Q3 		$464K Hold
57,472
– – 0.02% 497
2022
Q2 		$432K Hold
57,472
– – 0.02% 518
2022
Q1 		$540K Buy
57,472
+4,300
+8% +$35.9K 0.02% 531
2021
Q4 		$426K Hold
53,172
– – 0.01% 1546
2021
Q3 		$518K Hold
53,172
– – 0.01% 1438
2021
Q2 		$526K Buy
53,172
+4,200
+9% +$44.5K 0.01% 1490
2021
Q1 		$565K Hold
48,972
– – 0.01% 1338
2020
Q4 		$473K Sell
48,972
-4,400
-8% -$42.2K 0.01% 1390
2020
Q3 		$481K Sell
53,372
-3,400
-6% -$36K 0.01% 1245
2020
Q2 		$700K Buy
56,772
+10,000
+21% +$113K 0.01% 972
2020
Q1 		$420K Sell
46,772
-3,800
-8% -$38.9K 0.01% 1155
2019
Q4 		$496K Hold
50,572
– – 0.01% 1330
2019
Q3 		$348K Buy
50,572
+4,100
+9% +$31.4K 0.01% 1518
2019
Q2 		$429K Buy
46,472
+1,900
+4% +$22.9K 0.01% 1402
2019
Q1 		$699K Buy
44,572
+14,100
+46% +$249K 0.01% 1096
2018
Q4 		$470K Hold
30,472
– – 0.01% 1230
2018
Q3 		$656K Hold
30,472
– – 0.01% 1180
2018
Q2 		$741K Buy
30,472
+2,100
+7% +$42.8K 0.01% 1075
2018
Q1 		$485K Sell
28,372
-3,300
-10% -$64.4K 0.01% 1295
2017
Q4 		$600K Sell
31,672
-70,453
-69% -$1.06M 0.01% 1160
2017
Q3 		$1.8M Buy
102,125
+2,700
+3% +$60.8K 0.01% 972
2017
Q2 		$3.3M Sell
99,425
-7,700
-7% -$238K 0.02% 784
2017
Q1 		$3.44M Sell
107,125
-2,000
-2% -$68.3K 0.02% 769
2016
Q4 		$7.64M Buy
+109,125
New +$4.36M 0.05% 337

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s TEVA Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Teva Pharmaceuticals (TEVA) in Q2 2024, closing a stake of 43,972 shares — an estimated $620K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in TEVA in Q4 2016 and held it in 30 quarters. The position peaked at $7.64M in Q4 2016. 534 funds tracked by Wall St. Rank hold TEVA as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Teva Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 43,972 Teva Pharmaceuticals shares in Q2 2024, an estimated $620K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Teva Pharmaceuticals in Q4 2016 and held it in 30 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Teva Pharmaceuticals position peaked at $7.64M in Q4 2016.
  • 534 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.